ISO 20012-2026 PDF

ISO 20012-2026 PDF

Biotechnology-Biobanking-Requirements for human natural killer cells derived from pluripotent stem cells

$96.50 $193.00 -50%
Product Code: ISO 20012
Stock In Stock
Edition: 1.
Published: 02/2026
Number of Pages: 30
File Size: 1 file, 710 KB

Available Options

Product Description

Biotechnology — Biobanking — Requirements for human natural killer cells derived from pluripotent stem cells

Introduction: Natural killer (NK) cells, also known as large granular lymphocytes (LGL), are a type of cytotoxic lymphocytes belonging to the innate immune system. NK cells constitute 5 % to 15 % of the mononuclear cells and up to 20 % of lymphocytic population[1] in the peripheral blood. The expression patterns of activating receptors and inhibitory receptors determine the activating status and functionalities of NK cells. NK cells can eliminate pathogen-infected cells, cancerous cells, and other unhealthy cells by direct cytotoxicity. They express apoptosis-related ligands (TRAIL and FasL) and cytotoxic granules (granzymes and perforin) which can induce cell death in stressed cells. NK cells with the expression of CD16 can also kill antibody-coated target cells by antibody-dependent cell cytotoxicity (ADCC). As innate immune cells, NK cells are also engaged in reciprocal interactions with other immune cells to limit or exacerbate immune responses[2]. In adult, hematopoietic stem cells (HSCs) differentiate into common lymphoid progenitors (CLPs), then, give rise to NK progenitors (NKP). NKPs migrate into all lymphoid tissues or organs, and differentiate into mature NK cells subsequently[3]. However, NK cells can also arise from erythro-myeloid progenitors (EMPs) in the yolk sac. NK cells can be generated by induction from human pluripotent stem cells (hPSCs)[4]. Regarding the various tissue origins of natural NK cells during development, there also has been established various methods for

Scope: This document specifies requirements for the biobanking of human natural killer (NK) cells derived from human pluripotent stem cells (hPSCs), including the requirements for the differentiaton, culture, characterization, quality control, storage, thawing and transport of NK cells. Requirements for the collection of biological source material, the transport to and reception of biological source material and hPSCs at the biobank, as well as the establishment, expansion and QC of hPSCs are covered in ISO 24603. This document is applicable to all organizations performing biobanking of human NK cells used for research and development in the life sciences. This document does not apply to human NK cells for the purpose of in vivo application in humans, clinical applications or therapeutic use. NOTE International, national or regional regulations or requirements or multiple of them can also apply to specific topics covered in this document.

Be the first to write a review for this product.

Write a review

Note: HTML is not translated!
Bad           Good
ISO 20012-2026 PDF

ISO 20012-2026 PDF

$96.50 $193.00